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A B S T R A C T
Huntington's disease (HD) is a progressive neurodegenerative disorder that can be genetically conﬁrmed with
certainty decades before clinical onset. This allows the investigation of functional and structural changes in HD
many years prior to disease onset, which may reveal important mechanistic insights into brain function,
structure and organization in general. While regional atrophy is present at early stages of HD, it is still unclear if
both hemispheres are equally aﬀected by neurodegeneration and how the extent of asymmetry aﬀects domain-
speciﬁc functional decline. Here, we used whole-brain voxel-based analysis to investigate cross-sectional and
longitudinal hemispheric asymmetries in grey matter (GM) volume in 56 manifest HD (mHD), 83 pre-manifest
HD (preHD), and 80 healthy controls (HC). Furthermore, a regression analysis was used to assess the relationship
between neuroanatomical asymmetries and decline in motor and cognitive measures across the disease spec-
trum. The cross-sectional analysis showed striatal leftward-biased GM atrophy in mHD, but not in preHD, re-
lative to HC. Longitudinally, no net 36-month change in GM asymmetries was found in any of the groups. In the
regression analysis, HD-related decline in quantitative-motor (Q-Motor) performance was linked to lower GM
volume in the left superior parietal cortex. These ﬁndings suggest a stronger disease eﬀect targeting the left
hemisphere, especially in those with declining motor performance. This eﬀect did not change over a period of
three years and may indicate a compensatory role of the right hemisphere in line with recent functional imaging
studies.
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1. Introduction
Asymmetry is an inherent property of the human brain and has been
conﬁrmed in terms of both structure and function (Toga and Thompson,
2003). Variation in the neuroanatomical and functional organization
between the two brain hemispheres may arise from myriad diﬀerent,
often interdependent factors, including, but not limited to, develop-
ment, plasticity, and pathology (Toga and Thompson, 2003). In the
context of neurodegeneration, it is highly probable that disease-speciﬁc
processes would interact with the asymmetries of the healthy brain,
leading to either attenuated or increased lateralization. This has also
raised the question of whether disease progression equally aﬀects both
brain hemispheres. In Alzheimer's disease (AD), for instance, neuronal
loss appears to progress faster in the left hemisphere than in the right
(Thompson et al., 2003; Thompson et al., 2001; Wachinger et al.,
2016), suggesting a higher left-hemisphere susceptibility to neurode-
generation. However, others have reported greater cortical atrophy in
the right, rather than the left, hemisphere in mild cognitive impairment,
a pre-dementia stage of AD (Apostolova et al., 2007), which might in-
dicate stage-dependent diﬀerences in neuronal loss.
Similarly, the presence and progression of structural asymmetries in
Huntington's disease (HD) are still unclear. HD is a neurodegenerative
disorder that can be genetically conﬁrmed decades before formal clin-
ical diagnosis of motor onset (The Huntington's Disease Collaborative
Research Group, 1993). HD may serve as a model neurodegenerative
disorder and has the potential to advance our general understanding of
brain function and structure, as well as brain reorganization in the
presence of neurodegeneration. In HD, progressive regional brain
atrophy occurs well in advance of functional deﬁcits at the preclinical
stage of disease (preHD) and continues steadily after manifestation of
ﬁrst motor symptoms (mHD) (Ross et al., 2014). However, it remains
unclear whether neurodegeneration equally aﬀects both cerebral
hemispheres across all stages of the disease. A volume-based meta-
analysis of previously published voxel-based morphometry (VBM) stu-
dies found converging evidence of left-hemisphere lateralization of GM
loss in preHD prior to bilateralization at the clinical stage (Lambrecq
et al., 2013). However, just one cross-sectional study has explicitly
addressed brain asymmetry in HD, reporting bilateral GM loss in preHD
followed by left lateralization at later disease stages (Mühlau et al.,
2007). This study only included a very small sample of preHD partici-
pants (n = 9), leading to inconclusive results in terms of disease stage-
speciﬁc diﬀerences across the HD continuum. In a new VBM-based
meta-analysis, we also found converging evidence for more pronounced
atrophy of the left putamen in HD (Minkova et al., 2017), although the
number of studies analyzed was insuﬃcient to investigate the eﬀect
across diﬀerent stages of HD.
In the present study, we systematically assessed disease stage-spe-
ciﬁc diﬀerences in lateralization of GM atrophy in a large sample of
both pre-symptomatic (n = 83) and early stage (n = 56) HD mutation
gene-carriers, relative to healthy controls (n = 80). The analysis was
conducted following previous recommendations for whole-brain VBM-
based asymmetry analyses (Kurth et al., 2015). Furthermore, we in-
vestigated whether asymmetries in GM atrophy changed over three
consecutive years. Finally, we sought to assess the link between func-
tional decline and GM asymmetries in HD using regression analyses
with several motor and cognitive measures, selected based on previous
reports (Tabrizi et al., 2013). We hypothesized that GM lateralization
would be inﬂuenced by overall disease burden and may contribute to
the complex clinical phenotype and functional decline observed with
disease progression. More speciﬁcally, we expected to observe more
pronounced left-hemisphere vulnerability to neurodegeneration, espe-
cially in individuals closer to disease onset, which would be linked to
decline in cognitive and motor performance over time. Insights into the
patterns of hemispheric GM lateralization across the whole HD spec-
trum may provide valuable information in the context of disease-spe-
ciﬁc and compensatory mechanisms in HD and may be used to inform
future interventional studies.
2. Methods
2.1. Participants
Participants were recruited at four diﬀerent centers (London, Paris,
Vancouver, and Leiden) over four consecutive years (2008–2012) as
part of the TRACK-HD multi-center study (Tabrizi et al., 2013, Tabrizi
et al., 2012, Tabrizi et al., 2011, Tabrizi et al., 2009). A total of 366
participants were initially enrolled in the TRACK-HD study at visit 1
(i.e., baseline), of which 298 completed the 36-month follow-up. We
included only participants with a complete neuroimaging dataset (i.e., a
T1 scan acquired annually over four years) and excluded 44 individuals
with missing data. Another 35 participants were excluded because of
handedness (8 ambidextrous and 27 left-handers), since our study fo-
cused on brain asymmetries and we sought to avoid the potential
confounds due to handedness. Thus, the ﬁnal sample comprised a total
of 219 right-handed participants.
Each participant belonged to one of three groups: 56 mHD patients
with a clinical motor diagnosis, 83 preHD individuals without motor
symptoms but carrying the mutant huntingtin gene, and 80 healthy
controls (HC), who were age- and gender-matched to the combined HD
gene-carrier group. Disease status was assessed based on the Uniﬁed
Huntington's Disease Rating Scale (UHDRS-99), as reported at ﬁrst visit
(Tabrizi et al., 2009). Table 1 provides a summary of demographic and
clinical data. All participants were analyzed according to their group
membership and age at ﬁrst visit. No statistical diﬀerences were found
in gender and education among the three groups. In terms of age,
preHD were on average younger than mHD (p < 0.001). To control for
potential confounding eﬀects, age, gender, and site were included as
covariates in all analyses.
The study was approved by the local ethics committees and all
participants gave written informed consent according to the
Table 1
Sample characteristics.
HC (n = 80) preHD (n = 83) mHD (n = 56) Sig.
Age at baseline (years) 45.5 ± 20.1 (23–63) 41.2 ± 9.1 (19–64) 48.0 ± 10.0 (23–64) < 0.001
Sex (female/male) 48/32 41/42 30/26 0.062
Education (median, range) 4 (2–6) 4 (2–6) 4 (2–6) 0.891
CAG repeat length – 43.0 ± 2.4 (39–50) 43.8 ± 3.4 (39–59) < 0.001
Disease burden score – 291 ± 49 (171–409) 374 ± 82 (156–566) < 0.001
Adjusted net 36-month change in:
Symbol digit modality test – 6.04 ± 0.61 −8.78 ± 0.73 < 0.001
Indirect circle tracing – 0.16 ± 0.02 −0.24 ± 0.03 < 0.001
Q-motor speeded tapping – −0.35 ± 0.03 0.52 ± 0.05 < 0.001
Q-motor grip force – −0.33 ± 0.26 4.93 ± 0.64 < 0.001
The italic ﬁgures denote p values of t-tests (preHD vs. mHD). Signiﬁcance in age was tested using ANOVA, which signiﬁcance in sex was assessed using a chi-square test.
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Declaration of Helsinki prior to participation.
2.2. Cognitive and motor assessment
Participants completed a comprehensive battery of cognitive and
motor tests at baseline as well as at 12-, 24- and 36-month follow-up
visits. A full description of procedures and clinical outcomes is provided
elsewhere (Tabrizi et al., 2013, Tabrizi et al., 2012, Tabrizi et al., 2011,
Tabrizi et al., 2009). Only pre-selected cognitive and quantitative motor
(Q-Motor) measures that previously showed the highest rates of decline
at 36 months were used for the subsequent analyses (Tabrizi et al.,
2013). These included the following cognitive measures: symbol digit
modality test (SDMT; number of correct responses) and the indirect
circle tracing test (annulus length in log cm). Additionally, speeded
tapping (the log-transformed variability in inter-onset interval) and grip
force variability (log-transformed) of the non-dominant hand were used
as Q-Motor measures. Performance decline was deﬁned by the adjusted
net 36-month change in cognitive (SDMT and circle tracing) and Q-
Motor (tapping and grip force) measures, with higher values in cogni-
tive scores indicating improvement and higher motor scores, indicating
greater deterioration. Change in scores was estimated using a linear
mixed-eﬀects model including age, sex, and site as covariates. The
analysis was implemented in the lme4 package (Bates et al., 2015) for
the R computing program (R Core Team, 2016) and was conducted for
HD mutation gene-carriers only, since we were interested in the pre-
dictive value of disease-speciﬁc asymmetries for decline in perfor-
mance.
2.3. MRI acquisition
Scanning was performed on 3 Tesla whole-body scanners: Siemens
MAGNETOM TimTrio MR (Paris and London) and Phillips Achieva
(Vancouver and Leiden). High-resolution three-dimensional T1-
weighted structural scans were acquired for all participants with a
magnetization-prepared rapid gradient echo (MP-RAGE) sequence and
using standardized protocols, speciﬁcally developed for this multi-
center study, with the following parameters for the two scanner types,
respectively (Siemens/Philips): TR = 2200 ms/7.7 ms; TE = 2.2 ms/
3.5 ms; FA = 10°/8°, FOV = 28 cm/24 cm, matrix size of
256 × 256 × 208/224 × 224 × 164, and slice thickness of 1.0 mm,
with no inter-slice gap.
2.4. MRI data preprocessing
Structural MRI data preprocessing was performed using CAT12
v.953 (http://dbm.neuro.uni-jena.de/cat12/) and SPM12 v.6685
(Statistical Parametric Mapping, Welcome Trust Centre for
Neuroimaging, http://www.ﬁl.ion.ucl.ac.uk/spm), running on
MATLAB R2015a (Mathworks, Natick, MA, USA). All preprocessing
steps are illustrated in Fig. A.2 in the Appendix. The CAT12 processing
pipeline was based on recommendations for standardized VBM-based
asymmetry analyses (Kurth et al., 2015), accounting for voxel-wise
hemispheric correspondence. The pipeline was adapted for longitudinal
data by ﬁrst registering the longitudinal scans, as stated below.
Prior to preprocessing, all raw images were visually inspected for
potential artifacts. For each participant, the scans from all four time
points were then registered and bias-corrected using the serial long-
itudinal registration in SPM12, which combines diﬀeomorphic and
rigid-body registration and incorporates a correction for intensity in-
homogeneity artifacts (Ashburner and Ridgway, 2012). Speciﬁcally,
each time-point is a reoriented, spatially warped and intensity biased-
corrected version of the average T1-weighted scan, instead of the
baseline image, thus avoiding potential asymmetry biases. Thus, the
output consisted of an average T1 image and four Jacobian diﬀerence
maps, representing a measure of voxel compression (values < 1) and
expansion (values > 1) necessary for matching each visit scan to the
average image. To compute the rate of change over time, a within-
subject linear model was used to regress each Jacobian map against
time (in years). The resulting beta estimates (hereafter: voxel com-
pression maps; VCMs) were used for later quantiﬁcation of net grey
matter (GM) change.
Each participant's average image was segmented into GM, white
matter (WM), and cerebrospinal ﬂuid (CSF) using the CAT12 toolbox
with symmetric tissue probability maps (TPMs), computed by ﬂipping
and averaging. Spatial normalization was achieved by applying the
high-dimensional DARTEL approach (Ashburner, 2007), using a cus-
tomized study-speciﬁc symmetric template, which was created from the
original and ﬂipped GM and WM segments of the average T1 image, as
described elsewhere (Kurth et al., 2015). Flow ﬁelds were created fol-
lowing DARTEL normalization for later transformations into MNI space.
Net GM change was quantiﬁed by multiplying, voxel-by-voxel, the GM
segments with the VCMs (both in native space) and the resulting pro-
duct images were normalized into MNI space.
2.5. Asymmetry index calculation
To quantify asymmetries in GM volume at baseline and change over
time, separate asymmetry indices (AI) were computed based on the
average GM segments and the GM change maps, respectively, following
procedures described elsewhere (Kurth et al., 2015). Brieﬂy, normal-
ized average segments and change maps were ﬂipped at midline and the
resulting images were used to calculate the relative right-left diﬀerence
in brain size for each participant based on the following formula:
(Original− Flipped) / 0.5 × (Original + Flipped). Here, positive AI
values indicated rightward brain asymmetries, while negative – left-
ward asymmetries. A right-hemispheric mask was used to discard the
left hemisphere due to redundant information present in both hemi-
spheres1 and in order to avoid blurring across the midline during spatial
smoothing. Finally, the AI maps were smoothed with a kernel of 8-mm
full width at half maximum (FWHM) and the resulting images were
used for further statistical analyses.
2.6. Statistical analysis
Whole-brain statistical analyses were performed in SPM12 using the
spatially normalized and smoothed GM maps to assess whole-brain ef-
fects and the corresponding AI maps to analyze brain asymmetries.
Second-level general linear models were speciﬁed including the fol-
lowing three groups: HC, preHD, and mHD, as well as age, gender, and
site as covariates of no interest. Since AI denotes the relative right-left
diﬀerence in brain size and is not inﬂuenced by scaling eﬀects, total
intracranial volume (TIV) was only added as a covariate in the baseline
whole-brain VBM model. Statistical signiﬁcance was deﬁned at
p < 0.05 after cluster-level family-wise error correction (cFWE) for all
models. To assess whether whole-brain GM asymmetries were asso-
ciated with decline in cognitive and motor performance, regression
analyses were performed in SPM12 using the AI maps of all HD mu-
tation gene-carriers and the adjusted net 36-month change in scores as a
covariate. Separate models were deﬁned for each of the following four
scores that have been shown to have the highest rates of decline at
36 months: SDMT, indirect circle tracing, speeded tapping, and grip
force variability (Tabrizi et al., 2013).
3. Results
3.1. Whole-brain VBM results
The average GM volumes from the longitudinal registration step and
the percent annual GM change (the GM ∗ VCM product divided by 100)
1 Each hemisphere has the same asymmetry index values, but with a diﬀerent sign.
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were used to assess whole-brain volumetric diﬀerences within and be-
tween groups. The cross-sectional VBM analysis conﬁrmed the nu-
merous previous reports of localized bilateral striatal loss in preHD
relative to controls, while a more widespread bilateral neurodegen-
eration at the manifest stage was observed, including the occipital,
frontal, temporal, and parietal regions (Fig. 1). Longitudinally, GM
decline was observed bilaterally in the striatum and the occipital lobe in
preHD, as well as in the temporal and parietal regions in mHD (Fig. 2).
3.2. GM asymmetry results
The cross-sectional asymmetry analysis showed left-biased later-
alization of GM loss in the putamen, but only in mHD compared to
controls (Fig. 3). Longitudinally, neither within- nor between-group
diﬀerences were found in GM asymmetries.
3.3. Regression results
In HD mutation gene-carriers, GM volume at baseline was not pre-
dictive of net 36-month decline in indirect circle and Q-Motor grip force
variability (manumotography) tasks. However, we found associations
between GM volume at baseline and future cognitive (SDMT) and Q-
Motor ﬁnger tapping (digitomotography) decline. This included a po-
sitive correlation between decline in SDMT and lower GM volume in the
right inferior occipital cortex, right transverse temporal gyrus, left
thalamus, and the precuneus. Additionally, an association was found
between decline in Q-Motor ﬁnger tapping and lower GM volume in the
supplementary motor area and the precuneus (Fig. A.1 and Table A.1 in
the Appendix). Similarly, cognitive and motor decline was associated
with net 36-month change in GM volume in widespread fronto-striatal
and occipital regions, including also the precuneus. In terms of GM
asymmetries, no association was found at baseline, but longitudinally,
decline in Q-Motor ﬁnger tapping was linked to increasing asymmetries
of the superior parietal cortex, characterized by more pronounced GM
loss in the left than in the right hemisphere (Fig. 4). This result was
signiﬁcant at p < 0.05 cFWE-corrected and after Bonferroni correction
for the number of performed tests (n = 4).
4. Discussion
In this study, we investigated left-hemisphere vulnerability to neu-
rodegeneration in HD. In particular, our aim was to elucidate whether
patterns of asymmetric neuronal loss changed both according to disease
stage, and over time, in HD mutation gene-carriers. The cross-sectional
asymmetry analysis revealed a signiﬁcant left-sided lateralization of
striatal atrophy in the manifest HD stage, but not in preHD, which is
consistent with our initial hypothesis and with previous data (Mühlau
et al., 2007). Longitudinally, only bilateral GM loss was found across
the HD spectrum, with no evidence for a net 36-month change in GM
lateralization. In a regression analysis, we investigated whether
Fig. 1. Cross-sectional VBM between-group results: (a) healthy controls vs. pre-manifest HD; (b) pre-manifest HD vs. manifest HD; (c) controls vs. manifest HD. Results are signiﬁcant at
p < 0.05 cFWE. MNI coordinates: x = 7.5, y = 12, z =−8. L = left; R = right.
Fig. 2. Longitudinal change in GM volume over 36 months in (a) pre-manifest HD and (b) manifest HD, relative to controls (p < 0.05 cFWE). Results were adjusted for age, sex, study
site, and scan interval.
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Fig. 3. Cross-sectional VBM-based asymmetry results: (a) voxel-wise group diﬀerences (F-test) in GM asymmetries at p < 0.05 cFWE; (b) cluster-speciﬁc mean asymmetry index (AI)
among groups; (c) cluster-speciﬁc GM volumes for both hemispheres. Left putamen (in ml) was slightly smaller than the right one (p = 0.048).
Fig. 4. Association between motor decline and change in GM asym-
metries. Net 36-month decline in Q-Motor ﬁnger tapping variability
[digitomotography] was associated with change in GM asymmetries
in the superior parietal cortex with stronger GM loss in the left
hemisphere [x = 24, y =−39, z = 69] (t= 6.07, p = 0.006 cFWE).
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asymmetry in GM loss in HD mutation gene-carriers was related to
decline in cognitive and motor performance and found that lateraliza-
tion of GM loss in parietal regions was associated with decline in motor
performance when measured with sensitive, Q-Motor tests.
The left-sided lateralization of striatal atrophy found at baseline
adds to the growing evidence that the left hemisphere might be more
vulnerable to neurodegeneration, especially when individuals are close
to disease onset and their overall cognitive and motor abilities have
already started to deteriorate. For instance, deﬁcits in visuo-motor in-
tegration, as measured by the indirect circle tracing task, have been
shown to be positively correlated with atrophy of the left somatosen-
sory cortex (Say et al., 2011). Similarly, another study reported worse
visuo-motor and visual object performance linked to occipito-temporal
atrophy and decreased activity in the left fusiform cortex, in conjunc-
tion with increased activity in the left cerebellum (Wolf et al., 2014a).
Of note, the latter ﬁnding of cerebellar over-recruitment might indicate
a disease-speciﬁc eﬀect, i.e., a direct consequence of the disease rather
than a compensatory change, as recently discussed elsewhere (Cox
et al., 2015). In the working memory domain, lower functional con-
nectivity strengths were found between the right putamen and the left
superior frontal cortex during a working-memory task in preHD close to
clinical onset (Wolf et al., 2008). Finally, in our recent analysis ex-
plicitly investigating compensation (Klöppel et al., 2015), we provided
further evidence for a higher left-hemispheric susceptibility to eﬀects of
regional atrophy, linked to deﬁcits in the motor domain. In contrast, we
found indicators for a potential compensatory role of right parietal and
frontal areas, in relation to cognitive performance (Klöppel et al.,
2015).
A possible explanation is that asymmetries in GM loss are stage-
speciﬁc and become more pronounced in preHD after some time.
Surprisingly, our longitudinal asymmetry analyses did not show any net
36-month change in lateralization of GM loss, neither in preHD nor in
mHD. Instead, longitudinal whole-brain group comparisons indicated
bilateral progressive GM loss in both HD mutation gene-carriers,
especially in the occipital cortex and the precuneus, which is congruous
with the increased parieto-occipital disease-speciﬁc vulnerability sug-
gested in a recent study and linked to visuo-spatial deﬁcits in HD
(Labuschagne et al., 2016).
The lack of longitudinal asymmetry patterns in HD raised the
question of whether structural data alone are sensitive enough to detect
asymmetric disease progression over a short period of time.
Furthermore, HD group stratiﬁcation was based on disease burden
score (DBS) and at the presence of clinical motor symptoms as assessed
by the Uniﬁed Huntington's Disease Rating Scale Total Motor Score
(UHDRS-TMS) (Tabrizi et al., 2009), which might have failed to capture
the high heterogeneity of the whole HD spectrum. Since previous re-
ports of asymmetric GM loss have been linked to behavioral deﬁcits, we
conducted a regression analysis with all HD mutation gene-carriers,
including decline in pre-selected cognitive and sensitive Q-Motor as-
sessments as covariates. These included markers of cognitive perfor-
mance (SDMT and indirect circle tracing test) and Q-Motor measures
(ﬁnger tapping, [digitomotography] (Bechtel et al., 2010), tongue force
variability [glossomotography] (Reilmann et al., 2010b), and grip force
variability [manumotography] (Reilmann et al., 2010a), which have
previously been reported to have the greatest 36-month decline in HD
(Tabrizi et al., 2013). In clinical trial settings, Q-Motor measures ex-
hibited more sensitive to detect treatment eﬀects in the motor domain
than the UHDRS-TMS (Reilmann et al., 2015).
In the present study, 36-month decline in SDMT was found to be
correlated with lower GM volume at baseline in temporal and parieto-
occipital brain areas that are associated with cognitive and visuo-spatial
processing and selective attention, which is consistent with previous
data in HD (Johnson et al., 2015; Labuschagne et al., 2016; Nana et al.,
2014). Similarly, decline in Q-Motor ﬁnger tapping performance (i.e.,
higher variability in inter-onset intervals) was linked to lower GM vo-
lume at baseline in the supplementary motor area (SMA) and the
precuneus – areas involved in motor control and also known to be af-
fected in HD (Feigin et al., 2007; Klöppel et al., 2009; Rosas et al.,
2008). There was no association found between GM asymmetries at
baseline and decline in cognitive or Q-Motor measures. However, the
regression analysis using the longitudinal data showed a positive as-
sociation between decline in the ﬁnger tapping task and increased GM
asymmetries of the superior parietal cortex in HD mutation gene-car-
riers. More speciﬁcally, higher levels of ﬁnger tapping variability (i.e.,
deterioration in performance) was linked to more pronounced left
parietal GM loss, supporting the hypothesis of stronger disease eﬀects
targeting the left hemisphere in those with worse motor performance.
This is comparable to our previous study on compensation in preHD,
reporting a disease eﬀect in the left hemisphere and a compensatory
eﬀect in the right (Klöppel et al., 2015).
There are two main limitations of the present study. First, the
asymmetry analysis was based on voxel-based morphometry, which
does not take into account the contribution of anatomical properties
such as thickness, surface area, and gyriﬁcation. To address this issue,
surface-based analysis might be used in the future to conﬁrm our re-
sults. Recently, a novel technique has been proposed for examining
shape asymmetries of neuroanatomical structures (Wachinger et al.,
2016). Its application to studying Alzheimer's disease showed that
shape rather than sized asymmetries might be more sensitive to disease
progression. The second main limitation lies in the voxel-based char-
acter of the analysis focusing on GM changes only, lateralization on the
network level has not been considered. Recently, evidence has been
provided suggesting that brain regions with low structural connectivity
in the healthy brain, measured using DTI, showed the greatest increases
in resting-state functional connectivity in preHD, potentially indicating
a compensatory mechanism of functional connectivity accounting for
reduction in anatomical links between brain areas (McColgan et al.,
2017). Still, the nature of the enhanced functional connectivity at the
pre-manifest stage observed in some studies remains unclear. While it
may indicate compensation, it might also support the assumption of
excitotoxic processes proceeding neurodegeneration (for a review, see
Pievani et al., 2014). Irrespectively, data on structural and functional
asymmetries in HD on the network level are still lacking and need
further investigation.
Overall, this study showed some evidence for a HD-speciﬁc later-
alization of regional GM loss in more advanced stages of the disease,
which were associated with worsening of motor control functions when
assessed with sensitive Q-Motor measures. The inability to identify
changes in asymmetries in HD over the 3-year period might have re-
sulted from the high level of heterogeneity in terms of functional and
structural changes across the HD spectrum. More speciﬁcally, classical
analyses, focusing on the average eﬀect across a group, may not be
suﬃcient to identify subtle diﬀerence, which may provide valuable
insights into the pathomechanisms of the disease. Therefore, our results
warrant further assessment of brain lateralization to investigate dy-
namic changes in functional and structural alterations within and be-
tween individuals. Hypothetically, individuals with more pronounced
atrophy but intact functional capacities might employ a crucial parti-
cipant-speciﬁc compensatory process. However, the high within-group
variability among HD mutation gene-carriers may indicate that such
compensatory mechanisms are available to some but not all individuals.
A better understanding of the brain mechanisms underlying hemi-
spheric asymmetries in HD may prove useful for the development of
future interventions as well as for studying cognitive reserve and
compensation. Most importantly, HD may serve as a model disorder in
studying compensation in other neurodegenerative diseases, such as
Alzheimer's and Parkinson's, and may reveal important mechanistic
insights about how the unaﬀected brain compensates for eﬀects of
aging and neuronal loss.
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Appendix
Table A.1
Regression analysis results: correlations between decline in cognitive and Q-Motor scores and GM volume at baseline.
Hemi-sphere Coordinates [MNI] T p (cFWE)
x y z
Positive correlation with SDMTa
Inferior occipital gyrus R 52 −69 10 6.32 < 0.001
Transverse temporal gyrus R 50 −8 4 6.24 < 0.001
Precuneus L −3 −67 25 5.36 < 0.001
Thalamus L −16 −30 −3 5.13 0.004
Negative correlation with Q-Motor ﬁnger tapping variabilitya
Supplementary motor area L −3 10 49 5.59 < 0.001
Precuneus L −2 −69 36 5.05 < 0.001
a Lower scores in SDMT as well as higher Q-Motor ﬁnger tapping scores are both indicative of deterioration.
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Fig. A.1. Association between decline in behavioral scores and GM volume at baseline (cFWE-corrected). Both lower SDMT scores and higher Q-Motor ﬁnger tapping variability
[digitomotography] indicate decline in performance.
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Fig. A.2. Flowchart of the preprocessing pipeline. CSF = cerebrospinal ﬂuid, GM= grey matter volume, VCM= voxel compression map, WM= white matter volume.
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